Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 1,653,369 $ 1,677,932
General and administrative 871,675 779,254
Total operating expenses 2,525,044 2,457,186
Loss from operations (2,525,044) (2,457,186)
Interest income 90,488 464
Net loss (2,434,556) (2,456,722)
Other comprehensive income    
Foreign currency translation loss (10,800) (584)
Unrealized gain on investments 33,645 0
Comprehensive loss $ (2,411,711) $ (2,457,306)
Net loss per share:    
Basic and diluted $ (0.19) $ (0.19)
Weighted average shares outstanding:    
Basic and diluted 13,105,831 12,604,443